

Conventional, Complementary and Integrative Pain Therapies in a Military Population with chronic Musculoskeletal Pain: Results of a Pragmatic Clinical Trial using SMART Design

Ardith Doorenbos, PhD and Diane Flynn, MD

6 September 2024



- Neither Diane Flynn, MD, Ardith Doorenbos, PhD nor any co-investigators have conflicts of interest related to this research
- Opinions, interpretations, conclusions, and recommendations are those of the authors and do not necessarily reflect the official policy or position or are endorsed by the Department of the Army, Department of Defense, National Institutes of Health or the US Government. The investigators adhered to the policies for protection of human subjects as prescribed in 45 CFR 46.
- Funding: DOD, CDMRP, Neuromusculoskeletal Injuries Rehabilitation Research Award under Award No. W81XWH-18-2-0023. The National Institute of Health/National Institute of Neurological Disorders and Stroke. K24 AT011995.
- Approved for public release, Madigan Public Affairs Office, OPSEC and HRPO





Research Team



- Madigan Army Medical Center
 - COL(ret) Diane Flynn, MD, Protocol PI
 - MAJ(p) Jeff Ransom, DNP, PhD
 - Honor McQuinn, DNP
 - CPT Kira Heartwick, RD
 - Tyler Snow, DPT
 - James Martinez, RA

- University of Washington / University of Illinois – Chicago
 - Ardith Doorenbos, PhD, Grant Pl
 - Alana Steffen, PhD
 - Larisa Burke, MPH
 - Dahee Wi, PhD







- Physical and occupational therapies are standard rehabilitative care (SRC) for chronic pain
- A growing body of evidence supports complementary and integrative health (CIH) therapies, such as acupuncture, chiropractic, yoga and massage
 - Few studies have explored the optimal duration, sequence and combination of SRC and CIH to manage chronic pain





Primary Aim

 Is it better to start with SRC or with CIH in reducing pain impact?









Participants: Active-duty Service Members with chronic pain referred to the Madigan Army Medical Center Interdisciplinary Pain Management Center







Primary outcome measure: Pain Impact Score

- Recommended by NIH Task Force on Research Standards for Chronic Low Back Pain
- Composite measure of PROMIS
 - Pain interference (4-20 range)
 - Reverse Physical function (4-20 range)
 - 7-day average pain intensity (0-10 range)

Total range: 8 - 50







Secondary Outcome: Functional Performance

- Treadmill, Lift and Carry (TLC) Battery
 - Treadmill: walk/run on treadmill (METS)
 - Lift:
 - $\checkmark\,$ Lbs lifted from floor to waist
 - ✓ Lbs lifted from waist to shoulder
 - Carry: Lbs carried a distance of 40-ft
- Composite score:
 - 0-100 T-scale
 - MID = 7 points
- Measured by PT/OT professional



Snow T, Burke L, Sanford DC, Mathew A, Steffen AD, Flynn DM, Doorenbos AZ. Use of a treadmill, lift, and carry battery as a composite functional performance test: Analysis of data from a pragmatic randomized controlled trial in a military population participating in a functional restoration program. *Physiotherapy Theory and Practice*. 2024. 40(3): 647-657.





Sequential Multiple Assignment Randomized Trial (SMART) Design



Flynn DM, Eaton LH, Langford DJ, Ieronimakis N, McQuinn H, Burney RO, Holmes SL, & Doorenbos AZ. A SMART design to determine the optimal treatment of chronic pain among military personnel. *Contemporary Clinical Trials.* 2018; 73: 68-74.





Sequential Multiple Assignment Randomized Trial (SMART) Design

















































Statistical Methods

- Estimating MID for clinically relevant treatment response
 - Receiver Operating Characteristic (ROC) Curve Analysis
 - Euclidean ("Nearest") method
- Determining treatment response
 - Single time point general linear model regression
 - Regressed impact score on stage 1 treatment arm
 - Controlled for baseline impact score
 - $\checkmark\,$ Repeated for each timepoint
 - End of stage 1
 - End of stage 2
 - 3-month follow-up
 - 6-month follow-up





Defining Clinically Relevant Response to Treatment

"Compared to when you started study treatment, how would you rate your overall status?"









Receiver Operating Characteristic (ROC) Curve Analysis to determine MID







Other published estimates of PIS MID

Format, author, year	Study population	Anchor	MID method	MID	M	of of of	Greater worsening	No change	Greater improvement	
Paper survey; Deyo et al., 2016 ⁴	Rural Oregon prim care Chr MSK pain, n = 198, 66.5 years, PIS = 27.2, 62% women	Pain	Mean scor change between "/ little" and "Much" les pain	3		5	Much worse A little worse	About the same	A little less Much less	
Digital survey; Dutmer et al., 2019 ⁸	Dutch spine center, Chr LBP, n = 223, 49.7 years, PIS = 34.4, 58% women	Treated complaints	ROC cun – Euclidia distance	7.5	5	7	Extremely Much Little worsened worsened	Unchanged	Little Much improved improved improved	
Digital survey; Hays et al., 2021 ²	3 US military chiropractic practices, LBP (any duration), n = 749, 31 years, PIS 24.0	Low back pain	ROC cur e – Youden	7		7	Much worse A little worse	About the same	A little Moderately Much better better gone gone	
Two <	24% women	N/A				IΑ				
samples. No survey used; Hays et al., 2021 3	Chiropractic-seeking patients from 6 US states, Chr neck or back pain, n = 2024, 49 years, PIS 19.2, 72% women	N/A	Distributi methods SEM, SE SEP, RC	5-7	7	٧A	Distributive methods rather	than anchor-l	based survey were used to estimate MID	 Legend MID = minimal importany difference PIS = pain impact score
Digital CAT survey; current study, 2023	US military interdisciplinary pain management center, Chronic pain (any type), SMART Study n =192, PIS = 29.9 22% women IMPPPORT Study n = 85 PIS = 26.4 15% women	Pain intensity Physical functioning Pain interference Overall status	ROC curve – Euclidiar distance	3		7	Very much Much Minimally worse worse worse	No change	Minimally better better better MID threshold	 RCI = reliable change index ROC = receiver operating characteristic SEE = standard error of measurement SEP = standard error of prediction





Results - Demographics

	CIH	During Sta	ige 1	SRC I	<i>p</i> value		
Sex Male	n 106	% 75.7%	Mean (SD)	109	77.9%	Mean	NS
Age 18-24 25-34 35-44 45-64	17 59 49 14	12.2% 42.4% 35.3% 10.1%	34.4 (7.8)	11 64 51 14	7.9% 45.7% 36.4% 10.0%	35.1 (8.2)	NS
Race White Black Asian	81 31 24	57.9% 22.1% 17.1%		90 29 14	64.3% 20.7% 10.0%		NS
Marital status Married	96	68.6%		101	72.1%		NS
Education Some college Bachelor's degree	58 41	41.4% 29.3%		55 26	39.3% 18.6%		NS





	CIH Dur	ing Stage 1	SRC Durin	<i>p</i> value	
Pain type Musculoskeletal	n 124	% 88.6%	n 124	% 87.9%	\bigcap
Nerves/senses Other Missing	11 3 2	7.9% 2.1% 1.4%	10 4 3	7.1% 2.9% 2.1%	NS
Pain duration 1+ year	91	65.0%	85	60.7%	NS
Pain persistence Every/nearly every day	99	70.7	94	67.1	NS





	CII	H Treatm	nent Group	SRC	Treatme	ent Group	<i>p</i> value
Avg pain intensity Moderate (4-6)	n 95	% 67.9%	Mean T score (SD) 5.4 (1.5)	n 88	% 62.9%	Mean T score (SD) 5.5 (1.5)	NS
Pain interference Moderate	93	66.4%	64.0 (5.7)	91	65.0%	64.7 (5.8)	NS
Physical function Moderate impairment	80	57.1%	38.5 (4.4)	74	52.9%	38.2 (5.5)	NS
Anxiety WNL Moderate	53 45	37.9% 32.1%	57.0 (9.7)	42 42	30.0% 30.0%	57.6 (10.7)	NS
Depression WNL Moderate	54 36	38.6% 25.7%	55.3 (10.3)	61 37	43.6% 26.4%	54.8 (10.5)	NS
Anger WNL Moderate	65 35	46.4% 25.0%	55.1 (11.8)	61 35	43.6% 25.0%	56.3 (10.9)	NS





	CI	l Treatm	nent Group	SRC	Treatme	ent Group	<i>p</i> value
Avg pain intensity Moderate (4-6)	n 95	% 67.9%	Mean T score (SD) 5.4 (1.5)	n 88	% 62.9%	Mean T score (SD) 5.5 (1.5)	NS
Pain interference Moderate	93	66.4%	64.0 (5.7)	91	65.0%	64.7 (5.8)	NS
Physical function Moderate impairment	80	57.1%	38.5 (4.4)	74	52.9%	38.2 (5.5)	NS
Anxiety WNL Moderate	53 45	37.9% 32.1%	57.0 (9.7)	42 42	30.0% 30.0%	57.6 (10.7)	NS
Depression WNL Moderate	54 36	38.6% 25.7%	55.3 (10.3)	61 37	43.6% 26.4%	54.8 (10.5)	NS
Anger WNL Moderate	65 35	46.4% 25.0%	55.1 (11.8)	61 35	43.6% 25.0%	56.3 (10.9)	NS





	CIH	l Treatm	ent Group	SR	<i>p</i> value		
Sleep-related impairment Moderate Severe	n 57 27	% 40.7% 19.3%	Mean T score (SD) 62.7 (8.8)	n 63 20	% 45.0% 14.3%	Mean T score (SD) 62.2 (9.0)	NS
Fatigue Mild Severe	31 54	22.1% 38.6%	60.1 (9.2)	32 62	22.9% 44.3%	59.6 (8.5)	ŃS
Satisfaction with Social Roles and Activities Average Moderate dissatisfaction	59 59	42.1% 42.1%	38.2 (7.2)	51 58	36.4% 41.4%	38.1 (6.8)	NS





Results – Engagement in Treatment unrelated to Study

	CIH Treatn	nent Group	SRC Treatn	<i>p</i> value				
	Ba	Baseline through 6-months follow-up						
Medications NSAIDS (topical or oral)	53	37.9%	45	32 1%	\frown			
Muscle relaxants	25	17.9%	18	12.9%				
TCAs / SNRIs	40	28.6%	37	26.4%	NS			
Gabapentinoids	27	19.3%	30	21.4%				
Opioids	2	1.4%	2	1.4%				
Procedures								
Epidural steroid injections(s)	15 (10.7)	10.7%	16	11.4%				
Joint injection (non-spine)	10 (7.1)	7.1%	5	3.6%	NS			
Peripheral nerve block	7 (5.0)	5.0%	4	2.9%				
Trigger point injection(s)	7 (5.0)	5.0%	5	3.6%				
	End	End of Stage 2 through 6-months follow-up						
Additional SRC or CIH	83	59.3%	94	67.1%	NS			





Results – Engagement in Treatment unrelated to Study

	CIH Treatr	nent Group	SRC Treatm	<i>p</i> value					
	E	Baseline through 6-months follow-up							
Medications									
NSAIDs (topical or oral)	53	37.9%	45	32.1%					
Muscle relaxants	25	17.9%	18	12.9%					
TCAs / SNRIs	40	28.6%	37	26.4%	NS				
Gabapentinoids	27	19.3%	30	21.4%	110				
Opioids	2	1.4%	2	1.4%					
Procedures									
Epidural steroid inj(s)	15 (10.7)	10.7%	16	11.4%					
Joint injection (non-spine)	10 (7.1)	7.1%	5	3.6%	NS				
Peripheral nerve block	7 (5.0)	5.0%	4	2.9%					
Trigger point injection(s)	7 (5.0)	5.0%	5	3.6%					
	Enc	End of Stage 2 through 6-months follow-up							
Additional SRC or CIH	83	59.3%	94	67.1%	NS				





Sequential Multiple Assignment Randomized Trial (SMART) Design



















































Functional Performance (TLC battery) Outcomes by Stage 1 Treatment Group



Legend: † Mean improvement from baseline exceeded MID at 6-month follow-up, MID = 6 for TLC T-score





SRC start vs CIH Start – Outcomes Summary



Functional Performance







SRC start vs CIH Start – Clinical Implications

- Clinicians can feel confident recommending patients start with CIH therapies if that is the patients' preference
- Findings lend support to expanding access to CIH approaches







Questions

Thank you!







Additional slide

Secondary Aim and Results









Secondary Aim: Among non-responders to stage 1 treatment, determine the best follow-on approach

Outcome	Time point	Mean (SD)	Mean ƻ (95% Cl)	Mean (SD)	Mean ƻ (95% Cl)	P value	Switch i better	Combine is better
		CI	H → SRC	CIH	→ both			
	Pre-stage 1 Post-stage 1	26.6 (7.7) 27.0 (8.0)		31.3 (8.2) 31.6 (8.1)				
	Post-stage 2	6.3 (9.7)	2.3 (-0.2, 4.7)	29.6 (10.0)	-1.6 (-3.6, 0.5)	.022		
Pain impact	3 months 6 months	23.0 (11.0) 25.3 (9.9)	-3.4 (-6.5, -0.3) -1.1 (-3.9, 1.7)	31.9 (9.2) 30.4 (6.6)	-0.6 (-3.3, 2.0) 0 (-2.9, 2.8)	.205 .601		
score (8-50;		SR	C → CIH	SRC]		
nigner score =	Pre-stage 1	31.0 (8.1)		29.8 (7.9)]	
worse impact)	Post-stage 1	32.3 (7.5)		31.6 (7.2)				
	Post-stage 2	28.0 (9.5)	-1.8 (-3.6, 0.1)	28.1 (9.8)	-0.4 (-2.3, 1.5)	.320		_
	3 months	31.9 (10.4)	1.3 (-1.9, 4.5)	28.5 (9.3)	-0.5 (-3.8, 2.9)	.460		
	6 months	30.2 (9.5)	-0.5 (-3,2, 2,2)	30.7 (7.3)	1.3 (-1.4, 4.0)	.364		_
$^{a}\Delta$ = change in m	ean from pre-sta	age 1 baselin	e between SRC and	I CIH stage 1 gr	oups. CIH =		1.6-1.2 - 8 - 4 0	.4 .8 1.2
complementary a	& integrative, SR	C = standard	rehabilitative, TLC	= treadmill, lift	t, and carry batter	1.16	Cohen's d (9	5%)

- For non-responders to CIH start
 - It was better to combine SRC w/ CIH than switch to SRC alone
 - Only at end of active treatment, not at follow-up
- For non-responders to SRC start
 - No difference between switch to vs. combine with CIH



